United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

Shares of Germany-based BioNTech SE shot up 17.9% and Pfizer Inc. jumped 8.6% in premarket trading Monday, after the company's said their COVID-19 vaccine candidate achieved "success" in the first interim analysis of from a Phase 3 study. The companies said BNT162b2 vaccine candidate was found to be more than 90% effective in preventing COVID-19 in trial participants without previous evidence of SARS-CoV-2 infection.

BioNTech, Pfizer stocks soar after COVID-19 vaccine candidate achieves 'success' in first analysis

A leading coronavirus vaccine candidate worked to prevent people from developing COVID-19, a milestone in society's war against the pandemic. The pharmaceutical company Pfizer said Monday that its vaccine succeeded in the final stage of clinical trials, which compared tens of thousands of volunteers who received two doses of the experimental vaccine against a group receiving a saltwater placebo.

Pfizer says its coronavirus vaccine helps prevent COVID-19, marking a milestone in the fight against the pandemic

Interim analysis of vaccine by Pfizer/BioNTech far exceeds expectations of most experts

Covid-19 vaccine candidate is 90% effective, says manufacturer

Albert Bourla, chairman and CEO of Pfizer, hailed the development as a "great day for science and humanity."

Pfizer, BioNTech say late-stage trial data shows Covid vaccine is more than 90% effective in preventing infection

NEW YORK & MAINZ, GERMANY--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study. After discussion with the FDA, t

Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study

Ford Motor Company

JPMorgan Chase & Co

Lockheed Martin

Take a look at four value stocks from sectors that have underperformed lately. In addition to valuations, these stocks have robust dividend yield.

4 Strong Value Stocks for Savvy Investors Seeking 2021 Winners

Pfizer Inc. (NYSE: PFE) has disclosed in its earnings report that it received an official request for information from the US Securities and Exchange Commission, according to The Wall Street Journal. What Happened: The pharmaceutical company received formal requests regarding its operations in China and Russia from the SEC's foreign-bribery unit and the U.S. Justice Department in August and June.

Pfizer: SEC Foreign-Bribery Unit Has Formally Asked Company For Info

Inovio Pharmaceuticals

Moderna

The fate of this company's late-stage trial is now in the hands of the FDA.

November Is a Crucial Month for this Coronavirus Vaccine Stock

These top players may reach the finish line first -- and offer the world a new kind of vaccine.

Moderna and Pfizer: A Tale of Two mRNA Coronavirus Vaccine Stocks

What Are Your Chances of Getting a Coronavirus Vaccine by Year-End?

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today positive results from a Phase 3 investigational study evaluating the safety and efficacy of tofacitinib in adults with active ankylosing spondylitis (AS). Tofacitinib is not currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of AS. The study met its primary and key secondary endpoint of Assessment in SpondyloArthritis International Society (ASAS) 20 and 40 response, respectively, compared to plac

Pfizer Announces Positive Phase 3 Study Results for XELJANZ ® (tofacitinib) in Ankylosing Spondylitis (AS)

Mylan

There really isn't a downside to this deal.

3 Reasons Pfizer's Imminent Upjohn-Mylan Merger Is Great News for Investors

Novavax

Our indicative theme of Coronavirus Vaccine stocks – which includes a diverse set of U.S.-based pharma and biotech companies developing Covid vaccines – is up by about 560% year-to-date, on an equally weighted basis, compared to the S&P 500 which has gained just about 4% over the same period.

Moderna, Novavax, Pfizer: How Are Coronavirus Vaccine Stocks Faring?

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today further details regarding the proposed spin-off of its Upjohn Business and the subsequent combination of Mylan and the Upjohn Business to form Viatris Inc. As previously announced, Pfizer has set the close of business on November 13, 2020 as the record date for the spin-off, and the combination of Mylan and the Upjohn Business is expected to close on November 16, 2020. No action is required by Pfizer common stockholders to recei

Pfizer Announces Details for When-Issued and Ex-Distribution Trading of Viatris and Pfizer Common Stock

Amgen

Discovery

eBay

Macerich

Merck

Simon Property Group

Our call of the day offers up several stocks that busy, distracted investors have been overlooking. Smead Capital Management's CIO says they are stocks to hold for the long run.

Need to Know: These 7 unloved stocks are for the long haul, says contrarian manager

AstraZeneca

Australia has agreed to purchase another 50 million doses of two more COVID-19 vaccines, Prime Minister Scott Morrison said on Thursday, as Canberra aims to complete a mass inoculation programme within months.

Australia signs two more COVID-19 vaccine deals

Ionis Pharma

CARLSBAD, Calif. and BOSTON, Nov. 3, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary Akcea Therapeutics, Inc., today announced that Pfizer Inc. (NYSE: PFE) has initiated a Phase 2b study of vupanorsen (AKCEA-ANGPTL3-LRx) in statin-treated...

Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx)

Apple

Quest Diagnostics

NIKE

PayPal

As we near the end of 2020, it's time to safeguard your portfolio before we enter the new year. Here are the top stocks to buy in November.

7 Top Stocks to Buy for November

DexCom

Gilead Sciences

iShares Nasdaq Biotechnology ETF

IDEXX Laboratories

QuidelOrtho Corp

If you're interested in high-growth biotech stocks with superior fundamentals, here are which ones to consider, and which ones to skip. The post Which Biotech Stocks Are a Buy on Earnings?

Which Biotech Stocks Are a Buy on Earnings?

Pfizer Inc. (NYSE: PFE) will manage distribution of its COVID-19 vaccine on its own rather than through the U.S. government's designated coordinator, but officials question whether the U.S. has an adequate supply of medical-grade freezers at the point of use for vaccines requiring storage at ultra-cold temperatures. The Centers for Disease Control and Prevention in August tasked McKesson Corp. to be the central distributor for COVID vaccines and related supplies needed to administer vaccinations.

Pfizer to bypass US government system for COVID vaccine distribution

3 Reasons Pfizer and BioNTech's Coronavirus Vaccine Might Fail Even If It Works

Johnson & Johnson

No, the familiar "this will only sting a little" you hear from healthcare providers isn't one of them.

3 Things About Coronavirus Vaccines That You Almost Certainly Won't Like

The Federal Trade Commission has signed off on the deal.

Date Is Set for Merger Between Mylan and Pfizer's Upjohn Unit

The U.K. drug regulator is accelerating reviews of the coronavirus vaccines being developed by Pfizer and AstraZeneca, according to a report.

Regulators are accelerating reviews of COVID-19 vaccines from Pfizer and AstraZeneca, according to a report

HERTFORDSHIRE, England & PITTSBURGH & NEW YORK--(BUSINESS WIRE)--Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Federal Trade Commission (the “FTC”) accepted a proposed consent order, which concludes the FTC's review of the proposed combination of Mylan and Pfizer's Upjohn Business. The parties have now obtained all required antitrust clearances for the proposed transaction. The combination will be effected through a Reverse Morris Trust transaction, pursuant

News for Pfizer Stock (PFE)